openPR Logo
Press release

ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

11-13-2018 10:41 AM CET | Health & Medicine

Press release from: ISA Pharmaceuticals

/ PR Agency: akampion
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening keynote and award lecture of this year’s ESMO Immuno-Oncology Congress in Geneva, Switzerland, on December 13, 2018 (01:30-01:45 pm CET, Hall A2 – Room A). The title of his lecture will be “Combination immunotherapy of cancers caused by high risk human papilloma virus”.

Prof. Melief will be the second recipient of the ESMO Immuno-Oncology Award, which was created in 2017 in commemoration of European cancer research and treatment pioneer Prof. Georges Mathé, a founding member of ESMO.

In addition to his role at ISA Pharmaceuticals, Prof. Melief is Professor Emeritus in tumor immunology at the Leiden University Medical Center in the Netherlands. He focuses on the development of effective immunotherapies for virus-induced tumors and has created the concept of synthetic long peptide (SLP) vaccines for the treatment of cancer patients. Prof. Melief and his team were able to show the clinical effectiveness of these therapeutic vaccines in patients with pre-malignant lesions caused by Human Papilloma Virus type 16 (HPV-16).

Among the most promising results obtained to date, Melief and his team found that a combination of SLP vaccination and standard chemotherapy strengthened cervical cancer patients’ immune response and prolonged their survival. They further discovered that a similar effect could be achieved among patients with HPV-related head and neck cancer by administering the vaccines in conjunction with immunotherapy in the form of immune system boosting monoclonal antibodies.

Prof. George Coukos and John Haanen, Scientific Co-Chairs of the upcoming congress, outlined the reasons for nominating Cornelis Melief:

“Professor Melief dedicated his career to understanding how the immune system, specifically cytotoxic lymphocytes, interact with cancer, and used this knowledge for the development of new therapeutic cancer vaccine strategies,” said Coukos.

“With this award, we are recognizing him as a true pioneer in the field of cancer immunology, who has trained and inspired a whole generation of young scientists with his research,” Haanen added.

“This is a great honor and a wonderful recognition of the fact that after many years of concept building and evaluation in lab models and investigational trials, we have finally arrived at immunotherapy approaches that can make a difference for patients,” said Prof. Cornelis Melief. “To me, this award also means recognition of the outstanding teamwork delivered by talented investigators at Leiden University Medical Center and ISA Pharmaceuticals as well as by many medical oncologists in the Netherlands, Belgium and the USA.”

###

Contact & Media Inquiries:
akampion
Dr. Ludger Wess , Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, +49 30 23 63 27 68
info@akampion.com

About ISA Pharmaceuticals

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops SLP® immunotherapies to advance novel treatment options for orphan indications.

For more information, please visit www.isa-pharma.com.

SLP® and AMPLIVANT® are registered trademarks in Europe.

Miranda Molenaar
ISA Pharmaceuticals B.V.
J.H. Oortweg 19
2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
F: +31 71 33 22 311
E: info@isa-pharma.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018 here

News-ID: 1364403 • Views: 262

More Releases from ISA Pharmaceuticals

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019. The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute. The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC) Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810). This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019. The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00

All 5 Releases


More Releases for Prof

Prof. Igor Eleferenko appointed Dean of Al-Khalifa Business School
H.E. Prof. Sir Igor Eleferenko Ph.D. (Russian Federation) has been elected on 6th April 2020 as the Dean of Al-Khalifa Business School. Born on 23rd May 1958, in Moscow; in 1980 he graduated from Moscow State Pedagogical Institute named after M. Teresa. He has more than 40 years of experience as Associate Editor, Editor, Deputy Head of the APN Bureau in Havana, Deputy Editor-in-Chief, Editor-in-Chief of AVID APN, Editor-in-chief of TRK "TV-News"
Detailed research on Global and Chinese Temperature Meters Market just published …
Worldwide Temperature Meters Market report of 2019 provides a detailed market overview as well as industry analysis for/of companies, manufacturers and distributors covering data on gross margin, cost structure, consumption value, sale price and more. Temperature Meters Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Temperature Meters industry with a focus on the Chinese market. The report provides key
Banasthali Celebrates 87th Birthday of Dada Prof Diwakar Shastri
By nurturing Banasthali which is today one among the most sought after and top ranking women’s universities in India with global ranking, Prof Diwakar Shastri known to one and all as “Dada” built capacities for the spirit of inquiry, creativity and moral leadership among the enrolled girl students and became their role models. Known for his dignified unassuming personality, gleaming intellect, meticulous planning, deep regard for punctuality, far reaching vision and
MNIT Jaipur Prof SP Chaurasia Talk on Separation Technologies for Water Purifica …
Globally, there are over 663 million people living without a safe water supply close to home, spending countless hours queuing or trekking to distant sources, and coping with the health impacts of using contaminated water. 1.8 billion People use a source of drinking water contaminated with faeces, putting them at risk of contracting cholera, dysentery, typhoid and polio. The Sustainable Development Goals, launched in 2015, include a target to ensure
Prof Joy Mukhopadhyay Talks on Colour Science & Technology at Banasthali
One field which combines Chemistry, Physics, Physiology and Psychology is undoubtedly Colour Science and Technology. Global market size of dyes and pigments is of the order of USD 27.8 Billion with India market size of USD 4.9 Billion. Specialty chemicals, which comprise low volume, high value chemicals with specific applications, constitute a significant part of the Indian chemical industry include agrochemicals, flavors and fragrances, surfactants, polymer additives, personal care ingredients,
Prof. Dr. Thomas Gasser joins Beta Klinik
Bonn, Germany. Prof. Dr. med. Thomas Gasser has joined the Joint Practice at Beta Klinik for Neuroradiology, Neurosurgery, Radiology and Sports Medicine. Employing state-of-the-art therapies for the treatment of pain and movement disorders (neuromodulation, e.g. spinal cord stimulation – SCS, deep brain stimulation – DBS) are his primary focus as a physician. Additionally, he is specialized in the microsurgical treatment of neuro-oncological, degenerative and vascular brain and spine diseases. Prof. Dr.